Bieber Adrienne M, Marcon Ludovic, Hales Barbara F, Robaire Bernard
Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada.
J Androl. 2006 Mar-Apr;27(2):189-200. doi: 10.2164/jandrol.05103. Epub 2005 Nov 8.
Testicular cancer is the most common cancer affecting men of reproductive age. Advances in treatment of the disease, which include the coadministration of bleomycin, etoposide, and cis-platinum (BEP), have brought the cure rate to over 90%. This high cure rate, coupled with the young age of patients, makes elucidation of the impact of the treatment on reproductive function, fertility, and progeny outcome increasingly important. The goal of this study was to determine the effects of BEP, in doses analogous to those given to humans, on the male reproductive system, spermatozoa, fertility, and progeny outcome in an animal model. Male Sprague-Dawley rats were treated daily with BEP for 3 cycles of 3 weeks each, for a total of 9 weeks. After 6 and 9 weeks, males were mated to 2 groups of untreated females. BEP treatment resulted in decreases in testicular and epididymal weights of 52% and 28%, respectively, when compared to control. Decreased testis and epididymis weights were accompanied by impairment of spermatogenesis and by a decrease in spermatozoal count of nearly 90% (11.9 x 10(7) spermatozoa per caput epididymidis in control vs 1.65 x 10(7) in BEP-treated rats). The percent of motile spermatozoa in the treated rats was more than 30% lower than in controls. Defects in the flagella of spermatozoa increased by more than twofold in the midpiece, and by more than sixfold in the principal piece. Paternal BEP treatment, for either 6 or 9 weeks, did not affect fertility, pre- or postimplantation loss, litter size, or sex ratio among progeny on gestation day 21. In contrast, among the pregnancies allowed to proceed to delivery, a significant number of pups sired by males treated with BEP for 9 weeks died between birth and postnatal day 2; this was not observed in pups sired by males treated for 6 weeks. Markers of postnatal development were not affected in the surviving offspring from either group. Thus, despite the dramatic effects of the testicular cancer drug regimen on spermatogenesis, the numbers of spermatozoa, and their motility and morphology, male rats were fertile. While fetal development was apparently normal, early postnatal mortality, which may be associated with a delay in parturition, was elevated among the progeny sired by males exposed to BEP for 9 weeks.
睾丸癌是影响育龄男性的最常见癌症。该疾病治疗方法的进展,包括联合使用博来霉素、依托泊苷和顺铂(BEP),使治愈率超过了90%。这种高治愈率,再加上患者年龄较轻,使得阐明该治疗方法对生殖功能、生育能力和子代结局的影响变得越来越重要。本研究的目的是在动物模型中确定与给予人类剂量相似的BEP对雄性生殖系统、精子、生育能力和子代结局的影响。雄性Sprague-Dawley大鼠每天接受BEP治疗,共3个周期,每个周期3周,总共9周。在6周和9周后,将雄性大鼠与2组未治疗的雌性大鼠交配。与对照组相比,BEP治疗导致睾丸和附睾重量分别下降了52%和28%。睾丸和附睾重量的下降伴随着精子发生受损以及精子数量减少近90%(对照组每头附睾头部精子数为11.9×10⁷,BEP治疗组为1.65×10⁷)。治疗组大鼠中活动精子的百分比比对照组低30%以上。精子鞭毛中段的缺陷增加了两倍多,主段增加了六倍多。父本接受BEP治疗6周或9周,均不影响生育能力、着床前或着床后丢失率、窝仔数或妊娠第21天后代的性别比例。相比之下,在允许分娩的妊娠中,接受BEP治疗9周的雄性大鼠所生的大量幼崽在出生至出生后第2天之间死亡;而接受6周治疗的雄性大鼠所生的幼崽未观察到这种情况。两组存活后代的出生后发育指标均未受到影响。因此,尽管睾丸癌药物治疗方案对精子发生、精子数量及其活力和形态有显著影响,但雄性大鼠仍具有生育能力。虽然胎儿发育显然正常,但在暴露于BEP 9周的雄性大鼠所生后代中,早期出生后死亡率有所升高,这可能与分娩延迟有关。